Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic Adenocarcinoma.
Condition(s):Pancreatic AdenocarcinomaLast Updated:July 26, 2017Unknown status
Hide Studies Not Open or Pending
Condition(s):Pancreatic AdenocarcinomaLast Updated:July 26, 2017Unknown status
Condition(s):Lung Adenocarcinoma; Surgical Procedure, Unspecified; PathologyLast Updated:July 24, 2023Recruiting
Condition(s):Lung Neoplasms; Carcinoma Non-small-cell Lung; AdenocarcinomaLast Updated:November 7, 2023Active, not recruiting
Condition(s):Gastric AdenocarcinomaLast Updated:April 5, 2023Recruiting
Condition(s):Gastric and Cardia AdenocarcinomasLast Updated:August 14, 2023Recruiting
Condition(s):Lung AdenocarcinomaLast Updated:September 5, 2021Completed
Condition(s):Lung Adenocarcinoma; Whole Slide Image; Novel Grading SystemLast Updated:June 29, 2023Recruiting
Condition(s):Siewert Type II Adenocarcinoma of Esophagogastric JunctionLast Updated:January 30, 2018Completed
Condition(s):HER2-positive Advanced Gastric Cancer; HER2-positive Gastroesophageal Junction AdenocarcinomaLast Updated:March 12, 2024Recruiting
Condition(s):Pancreatic AdenocarcinomaLast Updated:January 10, 2013Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.